 Botulinum Toxins, Type A
"Botulinum Toxins, Type A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.
| Descriptor ID |
D019274
|
| MeSH Number(s) |
D08.811.277.656.300.480.153.100 D08.811.277.656.675.374.153.100 D12.776.097.156.100 D23.946.123.179.050
|
| Concept/Terms |
Botulinum Toxins, Type A- Botulinum Toxins, Type A
- Botulinum Neurotoxin A
- Neurotoxin A, Botulinum
- Clostridium botulinum A Toxin
- Clostridium Botulinum Toxin Type A
- Botulinum A Toxin
- Toxin, Botulinum A
- Botulinum Toxin Type A
|
Below are MeSH descriptors whose meaning is more general than "Botulinum Toxins, Type A".
Below are MeSH descriptors whose meaning is more specific than "Botulinum Toxins, Type A".
This graph shows the total number of publications written about "Botulinum Toxins, Type A" by people in this website by year, and whether "Botulinum Toxins, Type A" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 2 | 0 | 2 | | 2002 | 2 | 0 | 2 | | 2004 | 1 | 3 | 4 | | 2005 | 0 | 1 | 1 | | 2007 | 3 | 1 | 4 | | 2008 | 3 | 0 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 3 | 0 | 3 | | 2013 | 3 | 0 | 3 | | 2015 | 1 | 0 | 1 | | 2016 | 2 | 0 | 2 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 | | 2020 | 2 | 0 | 2 | | 2021 | 2 | 0 | 2 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Botulinum Toxins, Type A" by people in Profiles.
-
Reynolds WS, Suskind AM, Anger JT, Brucker BM, Cameron AP, Chung DE, Daignault-Newton S, Lane GI, Lucioni A, Mourtzinos AP, Padmanabhan P, Reyblat PX, Smith AL, Tenggardjaja CF, Lee UJ. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: Multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022 02; 41(2):662-671.
-
Brandon C, Pape DM, Oh C, Kreines FM, Thakker SS, Rosenblum N, Nitti VW, Brucker BM, Glass D. The Effect of Symptomatic Stress Urinary Incontinence on Catheterization Rates After Intradetrusor OnabotulinumtoxinA Injections. Female Pelvic Med Reconstr Surg. 2021 11 01; 27(11):676-680.
-
Suozzi KC, Kibbi N, Lee KC, Worley B, Furlan KC, Kang BY, Ibrahim SA, Poon E, Alam M. Development of Objective Structured Assessment of Technical Skills in facial cosmetic procedures: Botulinum toxin neuromodulator and soft-tissue filler injection. J Am Acad Dermatol. 2022 02; 86(2):463-467.
-
Palm MD, Few J, Patel T, Safa M, Drinkwater A, Mao C, Garcia JK. Efficacy, Patient-Reported Outcomes, and Safety for Millennial Subjects Treated With OnabotulinumtoxinA for Moderate to Severe Horizontal Forehead Lines. Dermatol Surg. 2020 05; 46(5):653-661.
-
Koskimäki J, Zhang D, Carrión-Penagos J, Girard R, Piedad K, Polster SP, Lyne S, Stadnik A, Awad IA. Symptomatic Brain Hemorrhages from Cavernous Angioma After Botulinum Toxin Injections, a Role of TLR/MEKK3 Mechanism? Case Report and Review of the Literature. World Neurosurg. 2020 Apr; 136:7-11.
-
Ballard TNS, Vorisek MK, Few JW. Impact of Botulinum Toxin Type A Treatment of the Glabella and Crow's Feet on Static Forehead Rhytides. Dermatol Surg. 2019 01; 45(1):167-169.
-
Gomelsky A, Athanasiou S, Choo MS, Cosson M, Dmochowski RR, Gomes CM, Monga A, Nager CW, Ng R, Rovner ES, Sand P, Tomoe H. Surgery for urinary incontinence in women: Report from the 6th international consultation on incontinence. Neurourol Urodyn. 2019 02; 38(2):825-837.
-
Bales GT. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con. J Urol. 2017 09; 198(3):500-501.
-
Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C. OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial. J Urol. 2017 02; 197(2S):S216-S223.
-
Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, De Ridder D, Jenkins B, Magyar A, Chapple C. Durable Efficacy and Safety of Long-Term OnabotulinumtoxinA Treatment in Patients with Overactive Bladder Syndrome: Final Results of a 3.5-Year Study. J Urol. 2016 Sep; 196(3):791-800.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|